Mansoor M. Amiji - Nanotechnology

Author Information

Mansoor M. Amiji is affiliated with the Department of Pharmaceutical Sciences at the School of Pharmacy, Northeastern University, located in Boston, MA, United States. His research focuses on nanotechnology and its applications in drug delivery and therapeutic interventions.

Research Contributions

Mansoor M. Amiji has made significant contributions to the field of nanotechnology, particularly in the development of novel delivery systems for therapeutics. His recent work includes combination microRNA-based cellular reprogramming for ovarian cancer treatment, systemic nano-delivery of STING agonists for cancer immunotherapy, and innovative approaches for CNS delivery of therapeutic oligonucleotides. Additionally, his research extends to the development of oral RNA interference therapies for celiac disease and nanotechnology-based strategies for overcoming drug resistance in chronic sinusitis with nasal polyps. The clinical approval of SARS-CoV-2 mRNA vaccines has also been a noteworthy area of his research, highlighting the impact of translational nanomedicine.

Aliases

Mansoor M. Amiji is also known by several aliases, including M M Amiji, Mansoor Amiji, M. Amiji, and Mansoor M. Amiji.

Publication and Citation Metrics

Metric	Value
Citation Count	25,289
h-index	89
Paper Count	410

Publications:

Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer

DOI: 10.1016/j.omto.2022.03.005

Year: 2022

Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.

DOI: 10.1016/j.jconrel.2022.03.054

Year: 2022

Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting

DOI: 10.3389/fphar.2021.660841

Year: 2021

Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine

DOI: 10.1007/s13346-021-00911-y

Year: 2021

Co-Silencing of Tissue Transglutaminase-2 and Interleukin-15 Genes in a Celiac Disease Mimetic Mouse Model Using a Nanoparticle-in-Microsphere Oral System.

DOI: 10.1021/acs.molpharmaceut.1c00322

Year: 2021

Role of vitronectin-rich protein corona on tumor-specific siRNA delivery and transfection with lipid nanoparticles.

DOI: 10.2217/nnm-2020-0428

Year: 2021

Oral RNA Interference Therapy for Celiac Disease using a Polymeric Microsphere Formulation

DOI: 10.21203/RS.3.RS-311580/V1

Year: 2021

P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.

DOI: 10.4193/Rhin20.551

Year: 2021

Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.

DOI: 10.1016/j.biomaterials.2021.120989

Year: 2021

Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.

DOI: 10.1016/j.jconrel.2021.01.027

Year: 2021

What is the Future of Biologics and Nanotechnology?

How Can Overheating Be Mitigated?

What is the Future of Nanocomposite Electrolytes?

What are Biological and Organic Materials in Nanotechnology?

How does Raman Spectroscopy contribute to Nanotechnology?

What is Flow Cytometry?

Can Nanotechnology Enhance Biomass Energy?

What is Stain Resistance in Nanotechnology?

How Does Marine Nanotechnology Contribute to Marine Biodiversity?

How are Researchers Addressing the Bandgap Issue?

Partnered Content Networks

Relevant Topics